Apr 12,2016

Livongo Health raises $44.5M for its cellular-enabled diabetes management system

Mountain View, California-based Livongo Health, the diabetes management company launched two years ago by former Allscripts CEO Glen Tullman, has raised $44.5 million from Merck Global Health Innovation Fund, Cowen Private Investments, Sapphire Ventures, Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts, and Wanxiang America Corporation. This brings the company’s total funding to at least $79.5 million.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Apr 19,2016

Roche partners with mySugr for Accu-Chek, Logbook app integration

About a year after pharmaceutical company Roche announced an investment in diabetes app company mySugr, the companies announced an integration partnership. MySugr offers a handful of apps, but its flagship is called Diabetes Logbook, which is designed for people with type 1 or type 2 diabetes and includes logging, graphing, analysis, and Apple Health integration. Users that own Roche’s Accu-Chek Connect meter will be able to automatically sync blood glucose data to mySugr. These users will also have access to the pro version of the mySugr app.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 07,2016

OurCrowd & Philips Join to Raise $3.5 Million for Sweetch MedTech Startup

Sweetch Health, an Israeli medtech startup that has developed a “digital vaccine” for diabetes, has received series A funding in the amount of $3.5 million. The funding round was led by global conglomerate Philips and leading equity crowdfunding platform OurCrowd. The funding also saw participation from earlier investors including Lionbird and Pontifax. Sweetch’s behavioral analytics engine may also be applied to other significant chronic diseases and pre-chronic disease states, such as pre-hypertension and hypertension, obesity and metabolic syndrome.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 08,2016

Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors to Ensure No Risk of Potential Conflict of Interest

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced that Henry Anhalt, DO, FACOP, FACE has stepped down from its board of directors. Dr. Anhalt is chief medical officer of T1D Exchange, a program of the nonprofit organization Unitio, that fosters collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes.

View Analyst & Ambassador Comments
Go to original news
Apr 14,2016

Tandem Diabetes Care Schedules First Quarter 2016 Earnings Press Release and Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, plans to release its first quarter 2016 results after the markets close on Thursday, April 28, 2016. The Company will hold a conference call and simultaneous webcast on the same day at 5:30 PM Eastern Time (2:30 PM Pacific Time), to discuss its first quarter 2016 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Apr 15,2016

Interim Clinical Data on Increased Measurement Frequency for sugarBEAT® CGM Released by Nemaura Medical

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT®, today announced further interim clinical data based on increased measurement frequency. The sugarBEAT® skin-patch is designed to display real time glucose readings on a reader via blue tooth, or allow retrospective data evaluation on a reader or mobile phone App. Nemaura today issued results of an interim study of eight patient day visits, consisting of five Type I diabetics, two of whom made two visits each, and one Type II insulin dependent diabetic patient, with up to 12 hours device wear time per day.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 27,2016

Brighter completes private placement of SEK 10.5 million and takes up a loan of SEK 10.5 million

In order to strengthen the Company's financial position, the Board has decided to conduct a private placement of SEK 10.5 million. The subscription price has been determined to SEK 2.33 per share through a bookbuilding process, which represents a discount of 15 percent on the last ten trading days’ volume weighted price.

View Analyst & Ambassador Comments
Go to original news
Apr 27,2016

Tandem Diabetes Care to Present at the Deutsche Bank 41st Annual Health Care Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 41st Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, May 4, 2016 at 9:20 AM Eastern Time (6:20 AM Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 28,2016

Tandem Diabetes Care Reports First Quarter 2016 Financial Results and Updates 2016 Guidance

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today reported its financial results for the quarter ended March 31, 2016 and updated its financial guidance for the year ending December 31, 2016. For the first quarter of 2016, operating expenses totaled $26.2 million compared to $23.2 million for the same period of 2015.

View Analyst & Ambassador Comments
Go to original news
Apr 28,2016

Insulet Reports First Quarter 2016 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced financial results for the three months ended March 31, 2016. First quarter 2016 revenue increased 69% to $81.2 million compared to $48.1 million in the first quarter of 2015.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES